Evidence map›Paper›PMID 40114059›Full record

ArticleMolecular medicine (Cambridge, Mass.)2025

Spatiotemporal diversity in molecular and functional abnormalities in the mdx dystrophic brain.

Joanna Pomeroy, Malgorzata Borczyk, Maria Kawalec, Jacek Hajto, Emma Carlson, Samuel Svärd, Suraj Verma, Eric Bareke, Anna Boratyńska-Jasińska, Dorota Dymkowska and 11 more

Abstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Joanna PomeroySchool of Medicine, Pharmacy and Biomedical Sciences, University of Portsmouth, White Swan Road, Portsmouth, PO1 2DT, UK.
Malgorzata BorczykDepartment of Molecular Neuropharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Str., 31-343, Krakow, Poland.
Maria KawalecMolecular Biology Unit, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland.
Jacek HajtoDepartment of Molecular Neuropharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Str., 31-343, Krakow, Poland.
Emma Carlson *Department of Human Genetics, McGill University, Montreal, QC, H3A 1B1, Canada.
Samuel Svärd *MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland.
Suraj Verma *School of Computing, Engineering and Digital Technologies, Teesside University, Middlesbrough, UK.
Eric BarekeDepartment of Human Genetics, McGill University, Montreal, QC, H3A 1B1, Canada.
Anna Boratyńska-Jasińska *Molecular Biology Unit, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland.
Dorota Dymkowska *Laboratory of Cellular Metabolism, Nencki Institute of Experimental Biology, Warsaw, Poland.
Alvaro Mellado-IbáñezSchool of Medicine, Pharmacy and Biomedical Sciences, University of Portsmouth, White Swan Road, Portsmouth, PO1 2DT, UK.
David LaightSchool of Medicine, Pharmacy and Biomedical Sciences, University of Portsmouth, White Swan Road, Portsmouth, PO1 2DT, UK.
Krzysztof ZabłockiLaboratory of Cellular Metabolism, Nencki Institute of Experimental Biology, Warsaw, Poland.
Annalisa OcchipintiSchool of Computing, Engineering and Digital Technologies, Teesside University, Middlesbrough, UK.
Loydie MajewskaDepartment of Pediatrics, McGill University, McGill Health Centre Glen Site, 1001 Decarie Blvd, EM02210, Montreal, QC, H4A 3J1, Canada.
Claudio AngioneSchool of Computing, Engineering and Digital Technologies, Teesside University, Middlesbrough, UK.
Jacek MajewskiDepartment of Human Genetics, McGill University, Montreal, QC, H3A 1B1, Canada.
Gennady G YegutkinMediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland.
Michal KorostynskiDepartment of Molecular Neuropharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Str., 31-343, Krakow, Poland.
Barbara ZabłockaMolecular Biology Unit, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland.
Dariusz C GóreckiSchool of Medicine, Pharmacy and Biomedical Sciences, University of Portsmouth, White Swan Road, Portsmouth, PO1 2DT, UK. darek.gorecki@port.ac.uk.

Funding

European Union COST Action CA21130 (PRESTO)
6 · The paper itself

Abstract

Duchenne muscular dystrophy (DMD) is characterized by progressive muscle degeneration and neuropsychiatric abnormalities. Loss of full-length dystrophins is both necessary and sufficient to initiate DMD. These isoforms are expressed in the hippocampus, cerebral cortex (Dp427c), and cerebellar Purkinje cells (Dp427p). However, our understanding of the consequences of their absence, which is crucial for developing targeted interventions, remains inadequate. We combined RNA sequencing with genome-scale metabolic modelling (GSMM), immunodetection, and mitochondrial assays to investigate dystrophic alterations in the brains of the mdx mouse model of DMD. The cerebra and cerebella were analysed separately to discern the roles of Dp427c and Dp427p, respectively. Investigating these regions at 10 days (10d) and 10 weeks (10w) followed the evolution of abnormalities from development to early adulthood. These time points also encompass periods before onset and during muscle inflammation, enabling assessment of the potential damage caused by inflammatory mediators crossing the dystrophic blood-brain barrier. For the first time, we demonstrated that transcriptomic and functional dystrophic alterations are unique to the cerebra and cerebella and vary substantially between 10d and 10w. The common anomalies involved altered numbers of retained introns and spliced exons across mdx transcripts, corresponding with alterations in the mRNA processing pathways. Abnormalities in the cerebra were significantly more pronounced in younger mice. The top enriched pathways included those related to metabolism, mRNA processing, and neuronal development. GSMM indicated dysregulation of glucose metabolism, which corresponded with GLUT1 protein downregulation. The cerebellar dystrophic transcriptome, while significantly altered, showed an opposite trajectory to that of the cerebra, with few changes identified at 10 days. These late defects are specific and indicate an impact on the functional maturation of the cerebella that occurs postnatally. Although no classical neuroinflammation markers or microglial activation were detected at 10 weeks, specific differences indicate that inflammation impacts DMD brains. Importantly, some dystrophic alterations occur late and may therefore be amenable to therapeutic intervention, offering potential avenues for mitigating DMD-related neuropsychiatric defects.

Indexed as

BrainMuscular Dystrophy, DuchenneAnimalsDisease Models, AnimalDystrophinMaleMiceMice, Inbred mdxTranscriptomeDystrophin

Identifiers

PMID40114059
PMCPMC11924731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.